1620 Investment Advisors, Inc. Biomarin Pharmaceutical Inc Transaction History
1620 Investment Advisors, Inc.
- $125 Million
- Q1 2025
A detailed history of 1620 Investment Advisors, Inc. transactions in Biomarin Pharmaceutical Inc stock. As of the latest transaction made, 1620 Investment Advisors, Inc. holds 1,428 shares of BMRN stock, worth $80,310. This represents 0.08% of its overall portfolio holdings.
Number of Shares
1,428
Previous 1,434
0.42%
Holding current value
$80,310
Previous $94,000
6.38%
% of portfolio
0.08%
Previous 0.07%
Shares
4 transactions
Others Institutions Holding BMRN
# of Institutions
668Shares Held
184MCall Options Held
1.24MPut Options Held
957K-
Black Rock Inc. New York, NY22.7MShares$1.28 Billion0.04% of portfolio
-
Vanguard Group Inc Valley Forge, PA19MShares$1.07 Billion0.03% of portfolio
-
Primecap Management CO Pasadena, CA17.8MShares$1 Billion1.06% of portfolio
-
Dodge & Cox San Francisco, CA15MShares$841 Million0.65% of portfolio
-
Viking Global Investors LP10.8MShares$607 Million2.55% of portfolio
About BIOMARIN PHARMACEUTICAL INC
- Ticker BMRN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 185,824,000
- Market Cap $10.5B
- Description
- BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...